We showed that PC inhibition caused by depleting MDM4 can be potentiated in cancers harbouring mutant p53, by co-treatment with eprenetapopt (APR-246), a first-in-class drug originally screened for its capacity to target mutant p53 cancers. This evidence concerns the gene TP53 and cancer.